Literature DB >> 27922752

Abnormal Glucose Metabolism and High-Energy Expenditure in Idiopathic Pulmonary Arterial Hypertension.

Gustavo A Heresi1, Steven K Malin2, Jarrod W Barnes2, Liping Tian2, John P Kirwan2,3, Raed A Dweik1,2.   

Abstract

RATIONALE: Insulin resistance has emerged as a potential mechanism related to the pathogenesis of idiopathic pulmonary arterial hypertension (IPAH). However, direct measurements of insulin and glucose metabolism have not been performed in patients with IPAH to date.
OBJECTIVES: To perform comprehensive metabolic phenotyping of humans with IPAH.
METHODS: We assessed plasma insulin and glucose, using an oral glucose tolerance test and estimated insulin resistance, and β-cell function in 14 patients with IPAH and 14 control subjects matched for age, sex, blood pressure, and body mass index. Body composition (dual-energy X-ray absorptiometry), inflammation (CXC chemokine ligand 10, endothelin-1), physical fitness (6-min walk test), and energy expenditure (indirect calorimetry) were also assessed.
MEASUREMENTS AND MAIN RESULTS: Patients with IPAH had a higher rate of impaired glucose tolerance (57 vs. 14%; P < 0.05) and reduced glucose-stimulated insulin secretion compared with matched control subjects (IPAH: 1.31 ± 0.76 μU/ml⋅mg/dl vs. control subjects: 2.21 ± 1.27 μU/ml⋅mg/dl; P < 0.05). Pancreatic β-cell function was associated with circulating endothelin-1 (r = -0.71, P < 0.01) and CXC chemokine ligand 10 (r = -0.56, P < 0.05). Resting energy expenditure was elevated in IPAH (IPAH: 32 ± 3.4 vs. control subjects: 28.8 ± 2.9 kcal/d/kg fat-free mass; P < 0.05) and correlated with the plasma glucose response (r = 0.51, P < 0.01). Greater insulin resistance was associated with reduced 6-minute walk distance (r = 0.55, P < 0.05).
CONCLUSIONS: Independent of age, sex, blood pressure, and body mass index, patients with IPAH have glucose intolerance, decreased insulin secretion in response to glucose, and elevated resting energy expenditure. These abnormalities are associated with circulating markers of inflammation and vascular dysfunction.

Entities:  

Keywords:  energy expenditure; glucose metabolism disorder; pulmonary hypertension

Mesh:

Substances:

Year:  2017        PMID: 27922752      PMCID: PMC5427733          DOI: 10.1513/AnnalsATS.201608-605OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  51 in total

1.  Metabolically active components of fat free mass and resting energy expenditure in nonobese adults.

Authors:  K Illner; G Brinkmann; M Heller; A Bosy-Westphal; M J Müller
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-02       Impact factor: 4.310

2.  O-linked β-N-acetylglucosamine transferase directs cell proliferation in idiopathic pulmonary arterial hypertension.

Authors:  Jarrod W Barnes; Liping Tian; Gustavo A Heresi; Carol F Farver; Kewal Asosingh; Suzy A A Comhair; Kulwant S Aulak; Raed A Dweik
Journal:  Circulation       Date:  2015-02-06       Impact factor: 29.690

3.  Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey.

Authors:  Charles D Burger; Aimee J Foreman; Dave P Miller; Robert E Safford; Michael D McGoon; David B Badesch
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

4.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

Review 5.  CXCR3, CXCL10 and type 1 diabetes.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Alda Corrado; Ele Ferrannini; Poupak Fallahi
Journal:  Cytokine Growth Factor Rev       Date:  2014-01-28       Impact factor: 7.638

6.  Mitochondrial hyperpolarization in pulmonary vascular remodeling. Mitochondrial uncoupling protein deficiency as disease model.

Authors:  Oleg Pak; Natascha Sommer; Timm Hoeres; Adel Bakr; Sharon Waisbrod; Akylbek Sydykov; Daniela Haag; Azadeh Esfandiary; Baktybek Kojonazarov; Florian Veit; Beate Fuchs; Friederike Christine Weisel; Matthias Hecker; Ralph Theo Schermuly; Friedrich Grimminger; Hossein Ardeschir Ghofrani; Werner Seeger; Norbert Weissmann
Journal:  Am J Respir Cell Mol Biol       Date:  2013-09       Impact factor: 6.914

7.  Exercise training decreases activation of the mitochondrial fission protein dynamin-related protein-1 in insulin-resistant human skeletal muscle.

Authors:  Ciaran E Fealy; Anny Mulya; Nicola Lai; John P Kirwan
Journal:  J Appl Physiol (1985)       Date:  2014-06-19

8.  Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial.

Authors:  Claudia E Ramirez; Hui Nian; Chang Yu; Jorge L Gamboa; James M Luther; Nancy J Brown; Cyndya A Shibao
Journal:  J Clin Endocrinol Metab       Date:  2015-11-18       Impact factor: 5.958

9.  Skeletal muscle dysfunction in idiopathic pulmonary arterial hypertension.

Authors:  Jane Batt; Samar Shadly Ahmed; Judy Correa; Alexandra Bain; John Granton
Journal:  Am J Respir Cell Mol Biol       Date:  2014-01       Impact factor: 6.914

10.  Evidence for the involvement of type I interferon in pulmonary arterial hypertension.

Authors:  Peter M George; Eduardo Oliver; Peter Dorfmuller; Olivier D Dubois; Daniel M Reed; Nicholas S Kirkby; Nura A Mohamed; Frederic Perros; Fabrice Antigny; Elie Fadel; Benjamin E Schreiber; Alan M Holmes; Mark Southwood; Guy Hagan; Stephen J Wort; Nathan Bartlett; Nicholas W Morrell; John G Coghlan; Marc Humbert; Lan Zhao; Jane A Mitchell
Journal:  Circ Res       Date:  2013-12-13       Impact factor: 17.367

View more
  17 in total

1.  Pulmonary Hypertension and Precision Medicine through the "Omics" Looking Glass.

Authors:  Jarrod W Barnes; Raed A Dweik
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

2.  Lipids and ketones dominate metabolism at the expense of glucose control in pulmonary arterial hypertension: a hyperglycaemic clamp and metabolomics study.

Authors:  Jacob T Mey; Adithya Hari; Christopher L Axelrod; Ciarán E Fealy; Melissa L Erickson; John P Kirwan; Raed A Dweik; Gustavo A Heresi
Journal:  Eur Respir J       Date:  2020-04-09       Impact factor: 16.671

3.  Exploring New Therapeutic Pathways in Pulmonary Hypertension. Metabolism, Proliferation, and Personalized Medicine.

Authors:  M Patricia George; Mark T Gladwin; Brian B Graham
Journal:  Am J Respir Cell Mol Biol       Date:  2020-09       Impact factor: 6.914

4.  Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure.

Authors:  Edda Spiekerkoetter; Elena A Goncharova; Christophe Guignabert; Kurt Stenmark; Grazyna Kwapiszewska; Marlene Rabinovitch; Norbert Voelkel; Harm J Bogaard; Brian Graham; Soni S Pullamsetti; Wolfgang M Kuebler
Journal:  Pulm Circ       Date:  2019-11-20       Impact factor: 3.017

Review 5.  Metabolic syndrome, neurohumoral modulation, and pulmonary arterial hypertension.

Authors:  Bradley A Maron; Jane A Leopold; Anna R Hemnes
Journal:  Br J Pharmacol       Date:  2020-02-18       Impact factor: 8.739

6.  Human PAH is characterized by a pattern of lipid-related insulin resistance.

Authors:  Anna R Hemnes; J Matthew Luther; Christopher J Rhodes; Jason P Burgess; James Carlson; Run Fan; Joshua P Fessel; Niki Fortune; Robert E Gerszten; Stephen J Halliday; Rezzan Hekmat; Luke Howard; John H Newman; Kevin D Niswender; Meredith E Pugh; Ivan M Robbins; Quanhu Sheng; Cyndya A Shibao; Yu Shyr; Susan Sumner; Megha Talati; John Wharton; Martin R Wilkins; Fei Ye; Chang Yu; James West; Evan L Brittain
Journal:  JCI Insight       Date:  2019-01-10

7.  Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension.

Authors:  Ghaleb Khirfan; Vickram Tejwani; Xiaofeng Wang; Manshi Li; Joseph DiDonato; Raed A Dweik; Nicholas Smedira; Gustavo A Heresi
Journal:  PLoS One       Date:  2018-05-29       Impact factor: 3.240

Review 8.  Malnutrition in pulmonary arterial hypertension: a possible role for dietary intervention.

Authors:  Chermaine T Kwant; Gerrina Ruiter; Anton Vonk Noordegraaf
Journal:  Curr Opin Pulm Med       Date:  2019-09       Impact factor: 3.155

9.  Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.

Authors:  Longfei Wang; Gunner Halliday; Joshua R Huot; Taijyu Satoh; Jeffrey J Baust; Amanda Fisher; Todd Cook; Jian Hu; Theodore Avolio; Dmitry A Goncharov; Yang Bai; Rebecca R Vanderpool; Robert V Considine; Andrea Bonetto; Jiangning Tan; Timothy N Bachman; Andrea Sebastiani; Charles F McTiernan; Ana L Mora; Roberto F Machado; Elena A Goncharova; Mark T Gladwin; Yen-Chun Lai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-09       Impact factor: 8.311

10.  Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Systemic Inflammation in Patients with Idiopathic Pulmonary Arterial Hypertension.

Authors:  Kamil Jonas; Wojciech Magoń; Piotr Podolec; Grzegorz Kopeć
Journal:  Med Sci Monit       Date:  2019-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.